Spotlight 02/09/19 | AMR Communication & Monitoring

AMR Communication

This week we had another reminder of the importance of AMR communication. After Dame Sally Davies’ interview to raise awareness of AMR on Sky News, we saw them run with a headline that AMR could ‘kill us before climate change does’, picked up by the Daily Express with a headline that ‘Antibiotics could kill 10m a year’ and tweeted by David Davies MP who likened the AMR threat to that of the 1918 Influenza epidemic. Lively discussion ensured on all three of these points: the relative threats of climate change and AMR; the challenges of conveying complex AMR terminology through the media; and the specifics of viral versus bacterial disease when discussing AMR. What links all three is the theme of threat. We now arguably life in a ‘public culture of danger’ and this is underscored by a new book published this week by journalist Bryan Walsh ‘End Times: A Brief Guide to the End of the World’ which follows a trend in the apocalyptic genre to examine worst-case scenarios that may end humankind – antimicrobial resistance is considered amongst asteroids, supervolcanoes, nuclear war, climate change and extraterrestrial intelligence.


AMR monitoring

Back to a more ‘actuarial’ model of AMR (see here for a distinction between this and the above ‘sentinel’ model) the WHO, FAO and OIE have just published a monitoring and evaluation framework for global and national implementation of AMR action plans. This includes core indicators across domains and is a must read for everyone hoping to feed into collaborative action on AMR. Likewise – please do respond to the current consultation on revisions to the Sustainable Development Goals which includes a proposal for a new AMR indicator, to ‘Reduce the percentage of bloodstream infections due to selected antimicrobial resistant organisms’. The indicator (3.d.2) is defined as ‘Frequency of bloodstream infection among hospital patients due to methicillin-resistant Staphylococcus aureus (MRSA) and Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli)’. Deadline for inputs is 8th September 2019.